Soc. Security Admin. Seeks Industry Help In Speeding Orphan Drug Coverage
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments
You may also be interested in...
"Regulatory Predictability" Is Key Barrier To Orphan Drug Development, Social Security Head Astrue Says
FDA's new leadership should focus on improving the "regulatory predictability" for orphan drug development, Social Security Administration Commissioner Michael Astrue said during a discussion of orphan drug policy sponsored by Shire Pharmaceuticals, the National Chamber Foundation and the U.S. Chamber of Conference in Washington, D.C. June 5
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.